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The melanocortin-4 receptor (MC4R) is expressed
in the brainstem and vagal afferent nerves and
regulates a number of aspects of gastrointestinal
function. Here we show that the receptor is also
diffusely expressed in cells of the gastrointestinal
system, from stomach to descending colon. Further-
more, MC4R is the second most highly enriched
GPCR in peptide YY (PYY) and glucagon-like peptide
1 (GLP-1) expressing enteroendocrine L cells. When
vectorial ion transport is measured across mouse or
human intestinal mucosa, administration of a-MSH
induces a MC4R-specific PYY-dependent antisecre-
tory response consistent with a role for the MC4R in
paracrine inhibition of electrolyte secretion. Finally,
MC4R-dependent acute PYY and GLP-1 release
from L cells can be stimulated in vivo by intraperi-
toneal (i.p.) administration of melanocortin peptides
to mice. This suggests physiological significance
for MC4R in L cells and indicates a previously unrec-
ognized peripheral role for the MC4R, complement-
ing vagal and central receptor functions.
INTRODUCTION
The melanocortin-4 receptor (MC4R) is a 7-transmembrane
(7TM) Gas-coupled receptor that plays an integral role in energy
homeostasis. Mutations causing loss of function of the MC4R
result in severe obesity with hyperphagia, hyperinsulinemia,1018 Cell Metabolism 20, 1018–1029, December 2, 2014 ª2014 Elseand increased somatic growth (Huszar et al., 1997). The MC4R
is expressed in up to 150 brain regions, with particularly high
expression in the paraventricular nucleus of the hypothalamus
(PVN) as well as in the dorsal motor nucleus of the vagus
(DMV) within the hindbrain (Mountjoy et al., 1994). Within these
brain regions, the MC4R responds to its endogenous agonist,
a-melanocyte stimulating hormone (a-MSH), and its endo-
genous antagonist, agouti-related protein (AgRP), which are
released from POMC neurons and AgRP/NPY neurons, respec-
tively. These inputs to MC4R neurons respond to a cascade of
homeostatic cues either from the circulation or through vagal
signals in order to regulate MC4R activity (Cone, 2005). Activa-
tion of the MC4R by a-MSH, or its synthetic analogs, generally
leads to weight loss (Hsiung et al., 2005), due to a reduction
in caloric intake and an increase in energy expenditure.
Conversely, blockade of MC4R by AgRP results in robust in-
creases in feeding as well as decreases in energy expenditure
(Graham et al., 1997; Ollmann et al., 1997). The MC4R knockout
(MC4R/) mouse expectedly exhibits severe obesity and hyper-
phagia (Huszar et al., 1997), with notable defects in acute re-
sponses to dietary fat and macronutrient preference (Butler
et al., 2001; Panaro and Cone, 2013). Study of the MC4R has
thus often focused on the mechanisms underlying the centrally
mediated effects of MC4R on feeding behaviors.
The MC4R also regulates gastrointestinal (GI) function. The
highest site of expression of the MC4R is in the DMV (Mountjoy
et al., 1994), the site of the preganglionic parasympathetic
vagal efferent nerves that regulate the GI system. Moderate
levels are also seen at the primary site of receipt of vagal affer-
ents in the nucleus of the solitary tract (NTS). Indeed, a third of
all vagal afferents in the nodose ganglion express MC4R, and
stomach and duodenum are innervated by MC4R-positive
vagal afferents and efferents (Gautron et al., 2010). Whilevier Inc.
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remain to be determined (e.g., see Richardson et al., 2013),
caudal brainstem administration of melanocortin agonists
inhibits food intake (Grill et al., 1998; Williams et al., 2000),
and injection of melanocortin agonists into either the DMV or
NTS decreases phasic gastric contractions (Richardson et al.,
2013). Stereotaxic injections into either the DMV or the
NTS of melanocortin agonists MT-II or a-MSH can modulate
gastric activity via vagal outflow to the stomach. This effect
was blocked by administration of melanocortin antagonist
SHU9119, vagotomy, or knockout of the MC4R (Richardson
et al., 2013). Thus, the melanocortin system is likely to affect
food intake not only through effects on behavioral centers in
the CNS but also secondarily, throughMC4R signaling involved
in the postprandial functions of the enteric nervous system
(ENS) (Gautron et al., 2010).
In relation to food intake, the GI tract functions in part by
releasing hormones that signal information about gut nutrient
content to other peripheral organs and the brain. These hormones
also functionwithin theGI tract to regulate nutrient and electrolyte
absorption. Prior to meal intake, P/D1 cells in the fundus of the
stomach release ghrelin, a hormone that acts to initiate a feeding
bout. Following ameal, several key peptides rise, including chole-
cystokinin (CCK) released from I cells in the duodenum (Lal et al.,
2004), gastric inhibitory peptide (GIP) released from K cells in the
duodenumand jejunum (Elliott et al., 1993), glucagon-like peptide
1 (GLP-1), and peptide YY (PYY) both released from L cells that
predominate in the distal ileum and colon (Elliott et al., 1993; Pili-
chiewicz et al., 2006). Both CCK and PYY3-36, an active cleavage
product of PYY, act as potent satiety factors that can reducemeal
size acutely (Batterham et al., 2002; Pilichiewicz et al., 2006), and
CCK requires brainstem MC4R signaling in order to reduce meal
size (Fan et al., 2004).
Control of GI hormone release from enteroendocrine cells
is mediated by a variety of signals, activated either apically by
luminal nutrients or basolaterally through stimulation by the
ENS or from the circulation. Many G protein-coupled receptors
(GPCRs) are expressed by enteroendocrine cells (Reimann
et al., 2008; Samuel et al., 2008), and PYY secretion has been
shown to be affected by GPCR activation, including the acyle-
thanolamine receptor GPR119, expressed on enteroendocrine
L cells. Apical or basolateral administration of a GPR119 agonist
to mouse or human colon mucosa suppresses electrolyte secre-
tion via endogenous PYY release and its subsequent binding
to nearby epithelial Y1 receptors (Cox et al., 2010). A previous
study detected MC4R mRNA by PCR in a mouse enterocyte
preparation. In this study, reduced intestinal expression of
microsomal triglyceride transfer protein (MTP) was seen in db/
db and MC4R/ mice (Iqbal et al., 2010). These data, along
with the absence of effect of vagotomy on intestinal MTP expres-
sion, were used to infer functional activity of leptin and melano-
cortin signaling in intestinal epithelial cells. More recently, gastric
ghrelin-positive cells were shown to highly express several
GPCRs, including the MC4R, with the potential to modulate
hormone secretion in response to neural or endocrine signals
(Engelstoft et al., 2013). The enrichment of GPCR expression in
gastric ghrelin-positive cells suggests that the MC4R may also
contribute directly to the regulation of hormone release via enter-
oendocrine cells. Given the discovery of MC4R in both vagalCell Metabneurons and ghrelin cells, and the suggestion of broader
MC4R expression along the length of the GI tract, we sought
to characterize MC4R expression and function in enteroendo-
crine cells, a crucial site in gut-brain communication and energy
homeostasis.
RESULTS
MC4R mRNA Expression Is Enriched in Some
Enteroendocrine Cell Populations
CCK-eGFP-, GIP-venus-, and GLP-1-venus-positive cells were
FACS purified from single-cell preparations of mucosal cells
generated from the proximal small intestine of transgenic
CCK-eGFP (Egerod et al., 2012), GIP-venus (Parker et al.,
2009), or GLP-1-venus reporter mice (Reimann et al., 2008),
respectively. cDNA from each of the purified enteroendocrine
cell populations was analyzed for melanocortin receptor expres-
sion by a qPCR array targeting 379 nonodorant 7TM receptors
(Figure 1), as previously reported for gastric ghrelin cells (Engel-
stoft et al., 2013). Among the five melanocortin receptors, the
MC4R was the only receptor expressed above background
levels in CCK (Figure 1A) and GLP-1 cells (Figure 1C), whereas
none of the melanocortin receptors were expressed above
background levels in GIP cells (Figure 1B). MC4RmRNAwas en-
riched 430-fold in the GLP-1 cells, thus being the second most
enriched receptor expressed in these cells (Figure 1C). In CCK
cells, MC4R mRNA was enriched 9-fold. Thus, MC4R is highly
expressed in particular in the GLP-1-positive enteroendocrine
cells.
L Cells Expressing GLP-1 or PYY Coexpress a
MC4R-GFP Marker
Tissue segments dissected from the GI tract of MC4R-Sapphire
mice, which express green fluorescent protein (GFP) under the
MC4R promoter (Liu et al., 2003), were collected to further char-
acterize cells expressing MC4R by fluorescence immunohisto-
chemistry, using antibodies to GFP, and GLP-1 or PYY, both of
which are expressed and secreted by L cells within the gut. Seg-
ments representing the stomach, duodenum, jejunum, ileum,
and colon were stained to detect coexpression of GFP and
PYY or GLP-1. When viewing tissues within the gut mucosa,
GFP-positive cells were present in occasional cells throughout
the GI tract from the stomach to the colon (Figure 2 and see Fig-
ure S1 available online). Also, L cells, marked by GLP-1 or PYY
staining, are sparse in all regions of the gut (Figure S1), although
they were most prominent in the colon (Figure 2), following the
expected L cell distribution pattern. As indicated by the merged
images, most cells positive for either GLP-1 (Figure 2A) or PYY
(Figure 2B) also coexpressed GFP. Cells expressing GLP-1 or
PYY, but lacking GFP, were also observed (white-lined arrows).
Three-dimensional reconstructions of the confocal data for both
PYY and GLP-1 colocalization with MC4R-GFP can be viewed
online in the Supplemental Information. Notably, in the stomach,
jejunum, and ileum, there were GFP-positive cells that did not
express PYY or GLP-1, lending a potential role for MC4R in other
populations aside from L cells, including potential nonepithelial
cell types (Figure S1). These results suggest that MC4R is ex-
pressed peripherally in several GI cell populations, and most
prominently in L cells.olism 20, 1018–1029, December 2, 2014 ª2014 Elsevier Inc. 1019
Figure 1. Expression of Melanocortin Receptors in Enteroendocrine Cells
Scattergrams exhibiting qPCR expression of the fivemelanocortin receptors (annotated green dots) among 379 7TM receptors (gray plus green dots) examined in
FACS-purified cells from the proximal small intestine from transgenic (A) CCK-eGFP, (B) GIP-Venus, and (C) GLP-1-Venus reporter mice (y axis) versus
expression in nonfluorescent mucosal cells (x axis). The 45-angled lines indicate the enrichment of expression in the fluorescent FACS-purified enteroendocrine
cells versus the neighboring enterocytes. The gray shaded area in each of the scattergrams is considered as noise level.
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Is Mediated by MC4R
Efforts to detect functional MC4R responses in semipurified
ex vivo preparations were met with limited success. Melanocor-
tin agonists induced ghrelin release from gastric mucosal prep-
arations (Figure S2A); however, melanocortin agonists, such as
a-MSH or LY2112688, were unable to induce GLP-1 release
frommouse colonic crypt preparations (Figure S2B). In contrast,
NDP-a-MSH and LY2112688 did elicit GLP-1 secretion from
mouse distal small intestine in perfusion experiments, though
the response was small compared to stimulation with neurome-
din C (Figure S2C). In addition, GLUTag cells, a line derived from
a GLP-1-positive L cell tumor (Drucker et al., 1994), exhibited a
functional MC4R response to multiple melanocortin ligands, as
measured using a phospho-ERK assay (Figure S2D).
To further examine whether MC4R expression in L cells has
functional significance, we next tested various MC4R agonists
on intestinal mucosae from MC4R+/+ and MC4R/ mice.
a-MSHwas applied either apically or basolaterally to different re-
gions of the intestinal mucosae, and changes in short-circuit cur-
rent (ISC) were measured. This electrogenic ion transport (most
likely apical Cl secretion) was stimulated first by basolateral
application of vasoactive inhibitory peptide (VIP), which binds
its epithelial receptor, VPAC, and via Gas-coupling propagates
an increase in ISC. Antisecretory effects after VIP pretreatment
were measured as rapid reductions in ISC (relative to the slowly
waning VIP response) and could result from locally released
PYY (or NPY) stimulating Gai-coupled epithelial Y1 receptors to
ultimately reduce Cl secretion (Cox et al., 2001, 2010). Basolat-
eral application of a-MSH reduced ISC levels rapidly and to a
significantly greater degree than apical peptide addition (Fig-
ure 3A), and consistently so in each of the four GI areas tested
(Figure 3B). The remaining VIP-elevated ISC was abolished by
subsequent addition of PYY, as indicated in the representa-
tive traces (Figure 3A). The antisecretory response profile to
a-MSH exhibited a similar regional distribution to that described
for L cell distribution in mice (Arantes and Nogueira, 1997).1020 Cell Metabolism 20, 1018–1029, December 2, 2014 ª2014 ElseFurthermore, the a-MSH responses were of similar magnitude
to those elicited by PSN632408 (PSN)-mediated GPR119 acti-
vation in the mouse jejunum and descending colon (dashed
lines, Figure 3B), an effect described previously (Cox et al.,
2010). When a-MSH was applied basolaterally to mucosae
from MC4R/ mice, the antisecretory responses were absent.
Importantly, responses to exogenous PYY (pooled data not
shown) and PSN were present in these tissues, and were
not significantly different from agonist responses in MC4R+/+
mucosae, suggesting otherwise normal mucosal transport and
L cell function in the MC4R/ mice (Figures 3C and 3D).
Concentration-response curves were constructed using a vari-
ety of basolaterally applied melanocortin receptor agonists, as
well as apically and basolaterally applied GPR119 agonist PSN.
Melanocortin receptor agonists exhibited between 10- and
1,000-fold higher potency than PSN (Figure 3E). EC50 values
(in nM) were 2.0, 2.1, 23.9, 459.1, and 684.8 for MT-II, NDP-
a-MSH, LY2112688, a-MSH, and ACTH, respectively, compared
with 4.8 mM and 4.2 mM for apical and basolateral PSN. The rank
order of potency of melanocortin peptides in the mucosal assay
paralleled that seen in tissue culture expression systems (Mount-
joyet al., 1994). Furthermore, pharmacological blockadeofMC4R
using theMC4R antagonist HS014 (Vergoni et al., 1998) was con-
centration dependent (Figure 3F). Taken together, these results
suggest that MC4R expression in the GI tract is functional, and
has the potential to regulate epithelial Cl secretion in a similar
manner to that described for GPR119 agonism. Interestingly,
this response appears to exhibit species dependence, since
melanocortin-induced PYY and GLP-1 release could not be de-
tected in the rat, using either ISC analysis from isolated mucosal
preparations, or perfused intestinal preparations (Figure S3).
Antisecretory Effects of a-MSH Are Y1 Receptor
Mediated and Glucose Sensitive in Mouse
and Human Colon
In mouse colon, a-MSH responses were not tetrodotoxin (TTX)
sensitive, suggesting that the response to a-MSH is mediatedvier Inc.
Figure 2. Immunohistochemical Character-
ization of MC4R Expression in L Cells of
the GI Tract
MC4R-Sapphire mice, which express GFP under
control of the MC4R promoter, were used to
visualize MC4R-expressing cells in the mucosa
of the colon. MC4R-positive cells are marked in
green with an antibody against GFP; L cells are
marked in red with antibodies against either (A)
GLP-1 or (B) PYY. L cells are found throughout
the GI tract, with highest frequency in the colon.
Cells positive for both GLP-1 or PYY and GFP in
the colon are visualized in the bottom panels.
While many colonic L cells are also MC4R
positive, there are L cells that do not coexpress
GFP, as marked with white-lined arrows. The
images are two-dimensional projections of three-
dimensional z stacks taken with a confocal mi-
croscope. The three-dimensional renderings are
available as supplemental videos. Scale bars
are 40 mm. See also Figure S1, Movie S1, and
Movie S2.
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stimulation (Figure 4A). In addition, pretreatment with the Y1
receptor antagonist BIBO3304 (BIBO) alone or together with
the Y2 receptor antagonist BIIE0246 (BIBO&BIIE) almost
completely blocked the effects of a-MSH (Figure 4A). Further-
more, testing of human colonic mucosa replicated the effects
of basolaterally applied a-MSH on ISC and separately shows
blockade by BIBO, but not by BIIE alone (Figure 4B), consistent
with the previous knowledge that Y2 receptors mediate
neuronal inhibitory mechanisms in mouse and human colon (Hy-
land et al., 2003). The same Y1 receptor mediation was seen for
the more potent a-MSH agonists MT-II, NDP-a-MSH and
LY2112688 (Figure S4). To ensure the specificity of MC4R in
the effect seen in human tissues, pretreatment with HS014 virtu-
ally abolished the antisecretory effects of a-MSH (Figure 4B).
HS014 also antagonized MT-II, NDP-a-MSH, and LY2112688
responses in C57BL/6J mouse colon, while not affecting PYY
activity (Figure S4). Taken together, these results suggest that
basolateral a-MSH reduces ISC via MC4R-stimulated release
of PYY and activation of Y1 receptors, in both mouse and hu-
man colon.
We characterized the glucose sensitivity of the MC4R res-
ponse by replacing glucose with mannitol on either the apical
or basolateral side of mouse colonic mucosa. Responses to
a-MSH were significantly inhibited when glucose was removed
from the basolateral surface only, in contrast with PYY re-
sponses, which were not glucose dependent (Figure 4C). Phlor-
idzin inhibits the cotransport of Na+ and glucose across apical
membranes via SGLT1 (i.e., it reduces ISC by inhibiting apical-
to-basolateral Na+ movement) and thus replacing apical glucose
only with mannitol rendered phloridzin significantly less active
(Figure 4C).
Tissue resistances were the same in MC4R+/+ and MC4R/
mucosa; however, basal ISC levels were significantly elevatedCell Metabin MC4R/ colon (p < 0.05), indicating loss of a mucosal anti-
secretory agent but otherwise normal mucosal barrier function
(Figure S5). Additionally, we observed that the competitive
MC4R antagonist HS014 alone increased basal ISC levels in
MC4R+/+ colon (3.6 ± 0.4 mA/cm2, n = 31, at 30 nM) and in hu-
man colon (6.0 ± 2.4 mA/cm2, n = 4, at 100 nM), indicating a
degree of MC4R-specific melanocortinergic tone in both
tissues.
We next monitored fecal pellet transit in isolated colon from
C57BL/6J mice in order to establish whether L cell activation re-
sults in slower colonic transit. In the presence of either a-MSH,
LY2112688, or GPR119 agonist PSN at the same concentrations
used in mucosal assays, colonic transit was inhibited signifi-
cantly (Figure S6), suggestive of endogenous PYY (and possibly
GLP-1) release resulting in slower colonic motility (Tough et al.,
2011).
MC4R Activation Produces Acute Release of PYY and
GLP-1 In Vivo
To test for functional effects of MC4R on L cells in vivo, we
administered LY2112688 and then assayed acute changes in
levels of circulating PYY. Mice were fasted for a minimum of
4 hr to attempt to avoid postprandial elevation of PYY. Further-
more, due to potential effects of stress, the mice were accli-
mated to handling with 7 days of vehicle i.p. injections prior
to the study day. In order to assess the contribution of the
MC4R to this response, we studied adult male MC4R+/+,
MC4R+/, and MC4R/ mice. Animals were given i.p. injec-
tions of LY2112688 at a dose of 3 mg/kg of body weight, or
an equal volume of saline (vehicle). At specific time points after
the injection, blood was collected in order to assay plasma
levels of PYY. At 10 min postinjection, there was a statistically
significant 3-fold rise in plasma PYY in MC4R+/+ mice





Figure 3. a-MSH Activity in Mouse GI Mucosae Occurs via MC4R
(A) Representative a-MSH (1 mM) responses in MC4R+/+ mouse descending colon mucosa to apical (ap) or basolateral (bl) addition. Basal short-circuit current
(ISC) values (in mA) are indicated to the left of each trace, and the exposed mucosal area was 0.14 cm
2. Mucosae were prestimulated with vasoactive intestinal
polypeptide (VIP, bl, 10 nM), after which bl a-MSH inhibited the VIP-elevated ISC, and subsequent bl addition of peptide YY (PYY, 10 nM) also inhibited ISC levels.
The vertical arrow shows the point at which the a-MSH-induced DISC was measured from the extrapolated VIP response (dashed line).
(B) Sensitivity to a-MSH (1 mM) added to bl (black bars) or ap (gray bars) compartments bathing WT mucosae from different GI areas. Mucosae were prepared
from jejunum, terminal (Term.) ileum, ascending (Asc.) colon, and descending (Desc.) colon. The horizontal dashed lines represent responses to the GPR119
agonist PSN632408 (10 mM, ap) in jejunum (jej) and descending colon. *p < 0.05, **p < 0.01, ***p < 0.001 comparing bl a-MSH with ap responses using one-way
ANOVA with Dunnett’s post test.
(C) Representative traces showing loss of a-MSH response in MC4R/ colon mucosa but normal GPR119 activity. Additions were in order, VIP (bl, 10 nM),
a-MSH (bl, 1 mM), or GPR119 agonist PSN632408 (ap, 10 mM) and finally PYY (bl, 10 nM).
(D) Regional GI sensitivity to a-MSH and PSN632408 inMC4R/mucosa. Responses to a-MSH (1 mM) were absent, while PSN632408 (ap, 10 mM) were normal.
Statistical differences, +p < 0.05, ++p < 0.01, +++p < 0.001; compare bl a-MSH responses in MC4R/ with those in MC4+/+ colon (in B).
(legend continued on next page)
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B Figure 4. a-MSH Activity in Mouse and
Normal Human Colon Mucosa Is Y1 and
MC4R Mediated, and Is Glucose Sensitive
(A) a-MSH (bl, 1 mM) in C57BL/6J mouse de-
scending colon mucosa after vehicle (Control),
tetrodotoxin (+TTX, bl, 100 nM) or the Y1 antago-
nist, BIBO3304 alone (+BIBO; bl, 300 nM)
or together with the Y2 antagonist, BIIE0246
(+BIBO&BIIE; bl, 1 mM), added 20 min prior to
a-MSH.
(B) In human colon mucosa a-MSH responses
(1 mM, bl) are also basolaterally targeted (ap re-
sponses in gray), BIBO3304 and HS014 sensitive,
but not BIIE0246 sensitive (+BIBO; 300 nM, +BIIE;
1 mM, or +HS014; 100 nM, each added alone,
30 min prior to bl a-MSH).
(C) Responses to a-MSH (1 mM, bl) are glucose
dependent in WT mouse descending colon
mucosa. In controls, KH buffer containing 11 mM
glucose bathed mucosa on both sides, whereas
11 mM mannitol (Mann) replaced glucose on
either ap or bl surface, and in the first histo-
gram resultant a-MSH responses (bl, 1 mM) are
shown. In the subsequent histograms, PYY
(10 nM, bl) responses 20 min after a-MSH and
finally the SGLT1 inhibitor, phloridzin (50 mM, ap,
gray bars) were added 15 min after PYY. Ap
mannitol only reduced apical SGLT1 activity and thus reduced the effect of apical phloridzin. Each bar is the mean 1 SEMwith n values in parenthesis. *p < 0.05
compared to respective controls using one-way ANOVA with Dunnett’s post test. See also Figures S3–S6.
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MC4R in L Cells Regulates PYY and GLP-1 ReleaseinMC4R+/ andMC4R/ groups (Figure 5A). A similar rise was
apparent in a different cohort at 25 min postinjection, while the
effect was blunted again in the MC4R+/ and MC4R/ mice
(Figure 5B). Lastly, in a cohort measured at 60 min postinjec-
tion, a statistically significant though much lower rise in PYY
still existed in MC4R+/+ compared with saline controls (Fig-
ure 5C). The increase in PYY following administration of
LY2112688 in lean WT animals could also be blunted by the
MC4R antagonist SHU9119 (Hruby et al., 1995), showing that
either genetic or pharmacological blockade of the MC4R blunts
the response (Figure 5F). Furthermore, intracerebroventricular
(i.c.v.) administration of two different potent MSH analogs,
LY2112688 and MTII, at doses known to induce MC4R-medi-
ated inhibition of food intake failed to induce a significant in-
crease in plasma PYY (Figure S7). Additionally, central admin-
istration of the MC4R antagonist, SHU9119, failed to block
the increase in plasma PYY induced by i.p. administration of
LY2112688 (Figure S7). Together, these experiments argue
that MC4R mediates a melanocortin-induced PYY release via
a peripheral site of expression. No increase in GIP or ghrelin
could be detected at 10 min post-LY injection, although there
were decreases in GIP levels in MC4R+/+ mice and a trend to-
ward lower ghrelin levels in MC4R/ compared to MC4R+/+
mice regardless of treatment (Figures 5D and 5E). The lack of
MC4R-mediated release of other hormones under these condi-
tions suggests an L cell-specific function for MC4R.(E) Concentration-response curves in WT descending colon for NDP-a-MSH, MT
PSN632408 added either ap (gray) or bl (black). EC50 values are quoted in the R
(F) MC4R antagonist HS014 inhibited a-MSH (1 mM) responses in WT mouse d
shown) 20 min prior to a-MSH (bl, 1 mM). Bars and points are the mean ± 1 SEM w
data points with control a-MSH responses using one-way ANOVA with Dunnett’
Cell MetabPharmacological and Physiological Properties of MC4R-
Stimulated GI Peptide Release In Vivo
In order to determine the importance of acclimation in the detec-
tion of this response, PYY levels were measured in adult male
C57BL/6J mice that were acclimated to handling and vehicle in-
jections for up to 7 days, and in age-matchedmice that were not.
In the group that was acclimated, there was a statistically signif-
icant 3- to 4-fold rise in fasting plasma PYY at 10 min postinjec-
tion of 3 mg/kg LY2112688 compared to vehicle-injected con-
trols (Figure 6A), consistent with that seen previously in the
MC4R+/+ group (Figure 5A). In the group that was not acclimated,
there was still a greater than 2-fold elevation in fasting plasma
PYY following the injection of LY2112688 compared to the con-
trol group (Figure 6B), suggesting that the rise in fasting PYY
levels in the circulation are only modestly affected by animal
handling and the expected HPA axis activation. In addition to
PYY release, L cells cosecrete the incretin GLP-1. Using plasma
samples from an independent cohort of unacclimated mice,
analyzed at 5 min posttreatment due to the extremely short
half-life of GLP-1, we measured a significant 1.4-fold increase
in GLP-1 in LY2112688- versus saline-treated mice (Figure 6C).
To further elaborate onMC4R-mediated gut peptide release, a
dose-response experiment was conducted in which animals
were injected with vehicle or varying doses of LY2112688
following a protocol with no acclimation period and a 4 hr fast
(Figure 6D). The rise in PYY followed a dose-response-II, LY2112688, a-MSH, and ACTH (all bl additions only), and for comparison
esults.
escending colon. Tissues were pretreated with HS014 (at the concentrations
ith n values shown in parenthesis. *p < 0.05, **p < 0.01, ***p < 0.001 compare
s post test. See also Figure S2.
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Figure 5. Intraperitoneal Injection of LY2112688 Increases Circulating PYY in an MC4R-Dependent Manner
Fasting plasma PYYwas assayed in adult maleMC4R+/+, MC4R+/, andMC4R/mice at (A) 10min, (B) 25min, and (C) 60min post-i.p. injection of either vehicle
or 3 mg/kg LY (A–C). The 10 min samples were also analyzed for differences in (D) Ghrelin and (E) GIP across all genotypes. (F) A submaximal dose of LY was
inhibited by also injecting 3 mg/kg SHU9119. Closed symbols denote vehicle treatment; open symbols denote LY treatment (unless otherwise noted). Lines
indicate mean + 1 SEM. Statistical significance was analyzed between treatments at each genotype using two-way ANOVA (A–E) or one-way ANOVA (F) with
Bonferroni’s post test. ***p < 0.001, **p < 0.01, *p < 0.05. See also Figure S7.
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MC4R in L Cells Regulates PYY and GLP-1 Releaserelationship, and the rise in plasma PYY at 10 min postinjection
was still robust at a dose as low as 0.3 mg/kg. Thus the release
of PYY is sensitive to MC4R agonist concentrations in ranges
used in prior pharmacological studies of the efficacy of melano-
cortin peptides in weight loss (Kievit et al., 2013). Treatment with
the endogenous agonist a-MSH (10 mg/kg) also produced a
statistically significant rise in plasma PYY relative to saline treat-
ment (Figure 6E).
DISCUSSION
MC4R expression is found in many brain nuclei (Mountjoy et al.,
1994), and these central MC4R sites control of multiple facets of
feeding behavior and metabolism (Cone, 2005). Central melano-
cortin signaling has also been implicated in the actions of periph-
eral adipostatic, hunger, and satiety factors such as leptin (Balth-
asar et al., 2004), ghrelin (Shaw et al., 2005), and CCK (Fan et al.,
2004). Additionally, data show that the central melanocortin sys-1024 Cell Metabolism 20, 1018–1029, December 2, 2014 ª2014 Elsetem may also regulate GI function. MC4R expression in vago-
vagal circuitry responsible for sensory and motor control of the
GI tract (Gautron et al., 2010) suggests that peripheral MC4R
functions deserve interrogation. In this study we demonstrate
expression of MC4R-GFP immunoreactivity in GI cells from
stomach to colon, and significant enrichment of MC4R in L cells.
Indeed,MC4Rwas one of themost highly enrichedGPCRs in the
GLP-1/PYY-positive L cells, second only to the GPR119 recep-
tor. This high level of enrichment of MC4R led to the hypothesis
that peripheralMC4Rmay play an important role in the regulation
of intestinal functions such as gut peptide release, and mucosal
ion transport and motility, complimentary to previously charac-
terized neuronal MC4R mechanisms.
Enrichment of MC4R Expression in L Cells
To further characterize MC4R expression in the gut, we focused
on MC4R expression in enteroendocrine L cells. L cells, which
are responsible for simultaneous secretion of PYY and GLP-1,vier Inc.



















































































































Figure 6. Injection of LY2112688 Increases Plasma PYY in a Dose-Dependent and Stress-Independent Manner and also Affects Circulating
GLP-1
Fasting levels of plasma PYY and GLP-1 were assayed in adult male C57BL/6J mice that were either acclimated or unacclimated to handling and i.p. injections.
(A) Mice acclimated to daily handling and i.p. injections exhibit a significant increase in plasma PYY levels 10 min after injection of 3 mg/kg LY.
(B) I.p. injections to unacclimated mice also exhibit a significant increase in plasma PYY levels 10 min after injection of 3 mg/kg LY.
(C) GLP-1 levels 5 min after injection of 3 mg/kg LY compared to vehicle-injected mice.
(D) Naive mice exhibit a dose-dependent increase in plasma PYYwith injections of vehicle, 0.003mg/kg LY, 0.03mg/kg LY, 0.3 mg/kg LY, 3 mg/kg LY, and 9mg/
kg LY. A near-maximal response was observed at a dose as low as 0.3 mg/kg LY.
(E) Fasting PYY levels exhibit a statistically significant rise in response to the endogenous melanocortin ligand a-MSH (10 mg/kg) in unacclimated mice at 10 min
post-i.p. injection. Closed symbols denote vehicle treatment; open symbols denote LY treatment. Lines and points are the mean ± 1 SEM (D and E). n is indicated
in parentheses except for (D) (five to six samples per point) and (E) (saline, n = 8; a-MSH, n = 9). Statistical significance was analyzed between groups using
Student’s t test. n = 5 (saline) or 6 (drug), ***p < 0.001, **p < 0.01, *p < 0.05.
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MC4R in L Cells Regulates PYY and GLP-1 Releaseexpress a high level of MC4R mRNA, as evidenced by qRT-PCR
analysis of 379 7TM receptors of FACS-purified L cell
populations marked by a GLP-1-driven reporter mouse line
(Figure 1C). MC4R expression was highest in the GLP-1-positive
cells, with a several-hundred-fold enrichment relative to non-
GLP-1 cells. Furthermore, we observed immunohistochemical
colocalization of MC4R expressing cells with PYY and GLP-1
using a reporter mouse line that expresses GFP under the
MC4R promoter (Liu et al., 2003) (Figure 2). Within the colon
most GLP-1 and PYY immunoreactive L cells were labeled as
MC4R-GFP positive; other cell types in the GI tract that appear
to express MC4R in these studies remain to be identified.
Functional Activity of the MC4R in L Cells
In isolated preparations of murine intestinal mucosae, we
observed robust MC4R anti-secretory responses upon stim-
ulation with melanocortin agonists. This primarily basolateralCell Metabresponse was indicative of paracrine PYY signaling, as it was
mediated by Y1 receptors expressed on epithelial cells (Mannon
et al., 1999). Importantly, a similar basolaterally directed Y1
dependence of MC4R antisecretory activity was revealed in
human colon mucosa, demonstrating conservation of this
regulatory pathway in human large bowel. An absence of this
response in rat intestine or colon was also noted. Blockade of
intrinsic submucosal neuron activity was ineffective in blocking
the a-MSH response, suggesting that functional contributions
from putative neuronal MC4R were not mediating the response
to exogenous a-MSH.
Removal of basolateral glucose significantly reduced the
antisecretory effects of a-MSH, and phloridzin’s dependence
on apical glucose for apically targeted SGLT1 activity was
evident. Thus, intestinal glucose-sensitive MC4R agonism is
similar to that observed for glucose-sensitive intestinal
GPR119 agonism (Cox et al., 2010), and compounds with clinicalolism 20, 1018–1029, December 2, 2014 ª2014 Elsevier Inc. 1025
Figure 7. Regulation of GI Epithelial Function by MC4R Activation
L cells receive basolateral regulatory input from enteric neurons, circulatory
factors, and paracrine agents. MC4R, targeted primarily to the basolateral
surface of L cells (as opposed to GPR119 which appears present on both
domains), is capable of inducing release of PYY and GLP-1 in response to
melanocortin peptides. The PYY release, up to two to four times above basal
levels in vivo, is sufficient to decrease local intestinal epithelial Cl secretion,
shown here, and inhibit motility (an example of another peripheral effect). The
physiological source of ligand remains to be determined but could be a-MSH
or another POMC melanocortin derivative.
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MC4R in L Cells Regulates PYY and GLP-1 Releasepotential targeted at these receptors should therefore exhibit a
reduced risk of hypoglycaemia.
Notably, MC4R activation also attenuated colonic transit time
to the same degree as GPR119 agonism, indicating the
potential that L cell-derived PYY and GLP-1 mediate colonic
brake and potentially more extensive inhibition, such as ileal
brake. Additionally, we showed that these intestinal mecha-
nisms were operative in vivo, by treating mice with a number
of peripherally delivered MC4R agonists. I.p. injections of
LY2112688 or a-MSH were able to induce statistically signifi-
cant, rapid rises in fasting plasma PYY and GLP-1 levels. Cen-
tral administration of two different potent melanocortin peptides
at doses known to inhibit food intake failed to produce a sig-
nificant rise in plasma PYY, while central administration of a
potent MC4R antagonist failed to block the PYY rise induced
by peripheral administration of the MC4R agonist LY2112688.
Together, these data support the hypothesis that MC4R expres-
sion on L cells is the primary mediator of melanocortin-induced
PYY release. Rises in plasma PYY traditionally occur in the
postprandial state and correlate with the activated cleavage
product, PYY3-36, a potent satiety factor that acts to reduce
meal size. While our assay did not distinguish between PYY1026 Cell Metabolism 20, 1018–1029, December 2, 2014 ª2014 Elseand PYY3-36, these peptides have the potential to alter food
intake through intestinal control and central action on satiety
and reward (Batterham et al., 2002). Similarly, the a-MSH-
induced GLP-1 release would be expected to exert an incretin
effect. Both the in vitro and the in vivo assays demonstrate
the requirement of MC4R for peripheral stimulation of L cells
as melanocortin agonists were ineffective in MC4R/ tissues
as well as in the MC4R/ animal studies, and in vivo
LY2112688-induced PYY release was blunted by administration
of the MC4R antagonist, SHU9119. The lack of a similar effect of
i.c.v. administration of the potent a-MSH agonist MTII argues
that CNS MC4R sites do not play a significant role in L cell
peptide release in these assays. Taken together, these data
argue for melanocortin-mediated PYY/GLP-1 release that re-
sults from activation of MC4R expressed specifically on L cells
(Figure 7).
Physiological Relevance of MC4R in L Cells
Our studies highlight a robust hormonal response to MC4R
activation that may have implications for behavioral and dietary
control that are separate but complimentary to the roles of
MC4R in the brain. Thus, a-MSH acting directly on the GI sys-
tem could be expected to enhance the incretin response, inhibit
GI functions such as ion transport and motility, and enhance the
release of satiety factors acting both on vagal nerves and
directly in the CNS. Our studies used exogenously applied
MC4R agonists to activate this response; however, analysis
of the basal function of MC4R+/+ versus MC4R/ colonic mu-
cosa supports the notion of endogenous activators of this
MC4R system as revealed by the higher basal ISC level of
MC4R/ mucosa and the acute prosecretory effect of the
MC4R antagonist, HS014 in mouse colon. However, the source
and identity of the endogenous ligand that might activate MC4R
in L cells remain unknown, and identification of the ligand is
critical for understanding the physiological role of this system.
Our studies indicate that MC4R is targeted to the basolateral
domain of L cells located in the small and large intestine,
arguing that the endogenous agonist is unlikely to activate
the receptor from the intestinal lumen (Figure 7). There are a
few possible sources for the endogenous ligand, including
hormones in the circulation, paracrine factors from the GI
epithelium, and neuronal stimulation from the ENS. The most
prominent circulating melanocortin agonist is ACTH, which is
released from the pituitary gland and is capable of binding
and activating MC4R in addition to MC2R. ACTH rises acutely
with stress and could theoretically activate L cell MC4R to
induce PYY release. However, no effect of a mild handling
stressor on baseline PYY levels was observed (Figures 6A
and 6B). Further, a more potent 25 min restraint stressor also
failed to alter plasma PYY levels (data not shown). In the GI
tract there have also been reports of immunoreactivity of
POMC-derived peptides, including g-MSH, b-endorphin, and
ACTH within the gastric mucosa (Tanaka et al., 1982), and
b-endorphin expression within mouse intestinal tuft cells (Gerbe
et al., 2011), and these may activate mucosal MC4R as indi-
cated in Figure 7. Future studies on immunohistochemical char-
acterization of POMC-expressing cells throughout the GI tract
and ENS may thus ultimately uncover a new MC4R-mediated
pathway that regulates GI function and feeding behaviors.vier Inc.
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Expression
Due to its integral role in energy homeostasis and human
syndromic obesity, the MC4R is a well-validated drug target. Or-
thosteric agonists of the MC4R, including the peptide
LY2112688, failed in clinical trials due to deleterious target-
mediated pressor effects despite successful reduction in
body weight in multiple animal models (Greenfield et al., 2009).
Interestingly, a near-maximal PYY response was noted at
LY2112688 doses as low as 0.3 mg/kg (Figure 6), similar to
doses of melanocortin peptides previously shown to be suffi-
cient to induce weight loss in primates (Kievit et al., 2013).
More recently, the peptide agonist RM-493 has been described
that causes significant weight loss in primates without a rise in
blood pressure or heart rate following peripheral administration
(Kievit et al., 2013). A speculative hypothesis is that the latter
compound may have reduced brain penetrance, and that devel-
opment of melanocortin agonists that lack extensive penetration
of the blood-brain barrier may allow weight loss without un-
wanted pressor side effects. If stimulation of MC4R in L cells
and other peripherally located MC4R can mediate effects on
energy homeostasis, this is an important shift in current thinking
about the melanocortin system and drug development at the
MC4R.
Finally, the rapid and robust in vivo release of PYY also repre-
sents a useful biomarker for MC4R receptor occupancy in vivo.
At a time point only 10 min after injection of LY2112688, we
consistently observed a MC4R-dependent 2- to 4-fold increase
in plasma PYY. By simply assaying PYY levels, one can deter-
mine if MC4R is being activated in vivo without the time or
expense associated with typical readouts like food intake and
body weight changes. Such a facile bioassay is particularly use-
ful for in vivo screening approaches that seek to rapidly verify re-
ceptor occupancy of MC4R-targeted drugs. In conclusion, the
signaling pathway elucidated here reveals a potentially signifi-
cant peripheral MC4R activity on mouse and human GI function.
The MC4R may thus also be included in the growing group of
GPCRs with enriched expression on GI enteroendocrine cells
with therapeutic potential in diabetes and obesity (Schwartz
and Holst, 2010).EXPERIMENTAL PROCEDURES
Fluorescence-Assisted Cell Sorting and qPCR
Single-cell suspensions were made by mechanic and enzymatic disruption of
small intestinal tissue from reporter mice and separated into fluorescence-
positive cells and fluorescence-negative cells as described (Egerod et al.,
2012; Parker et al., 2009; Reimann et al., 2008). cDNA from FACS-purified cells
was used to examine expression of melanocortin receptors using custom-de-
signed 384-well qPCR plates, as described (Engelstoft et al., 2013). These pro-
cedures were performed in accordance with the Institutional Animal Care and
Use Committees at the University of Copenhagen.
Immunohistochemistry
MC4R-Sapphire C57BL/6J transgenic mice were used to detect MC4R-
expressing cells by immunohistochemical fluorescent labeling of a tau-GFP
fusion protein under control of the MC4R promoter (Liu et al., 2003). Males
aged 7–8 weeks were subjected to a daytime fast of 4 hr in order to minimize
the presence of intestinal food matter. The mice were deeply anesthetized us-
ing inhaled isoflurane and sacrificed by cervical dislocation. The peritoneal
cavity was exposed and GI tract removed from stomach to rectum. SegmentsCell Metabmeasuring 1 cm were removed from the glandular stomach (distal end),
duodenum (adjacent to the pyloric sphincter), jejunum (halfway between the
pyloric sphincter and the ileocecal valve), ileum (3 cm above the ileocecal
valve), and colon (halfway between the cecocolic junction and anus). Seg-
ments were cleared by flushing with ice-cold PBS using a syringe and 12 g
needle until clean, then transferred to individual 15 ml tubes filled with 4%
PFA (pH 7.2) in PBS and left for 24 hr at 4C. After fixation, the tissues were
transferred to 20% sucrose in PBS for 48 hr at 4C. Tissues were then dabbed
of excess fluid, laid flat, and frozen in a base mold with O.C.T. compound
(Tissue-Tek #4583) and stored at 80C.
Slide-mounted tissue (10 mm) sections were permeabilized for 30 min with
0.5% Triton X-100 in PBS at room temperature (RT). Nonspecific binding
was blocked with 10% normal donkey serum in PBS containing 0.1% Triton
X-100 for 1 hr at RT. Sections were then incubated in primary antibody in
PBS containing 0.1% Triton X-100 for 2–3 days at 4C, followed by 4 3
10 min PBS washes. Sections were then incubated overnight at 4C with sec-
ondary antibodies in PBS containing 0.1% Triton X-100. Finally, sections were
washed with PBS (4 3 10 min) with DAPI included in the first wash (1:50,000)
and then coverslipped with PolyAquamount (Polysciences). All staining steps
except for washes were done in a humidified chamber with 100–200 ml of re-
agent per slide, each slide temporarily covered with a glass coverslip during
incubation steps.
Primary antibodies used included chicken anti-GFP (1:1K, Abcam
#ab13970), rabbit anti-GLP-1 (1:1K, Phoenix Pharmaceuticals #H-028-13),
and rabbit anti-PYY (1:1K, Abcam #ab22663). Secondary antibodies included
donkey anti-rabbit Alexa 546 (1:1K, Invitrogen) and donkey anti-chicken cy5
(1:1K, Jackson ImmunoResearch).
Control slides without primary antibodies were used in addition to immuno-
staining for GFP in littermate WT mice.
Images of fluorescently labeled gut sections were taken with a Zeiss 710
confocal microscope equipped with a 633/1.4 N.A. Plan Apochromat oil
lens. Excitation/emission wavelengths (nm) for each fluorophor were as fol-
lows: DAPI, 405/410–505; Alexa 546, 561/568–610; cy5, 633/638–759. Image
analysis was done with Imaris (version 7.6.0). The animal procedures
described above were approved by the Vanderbilt University Animal Care
and Use Committee.
Measurement of ISC
GI tissue from adult (12–20 week old) male C57BL/6J, MC4R+/+, or MC4R/
mice or clinical specimens were dissected free of overlying smooth muscle
and mucosae placed between two halves of Ussing chambers, exposing an
area of 0.14 cm2. Mucosae were bathed both sides with Krebs-Henseleit
(KH) buffer of following composition (in mM: 117 NaCl, 24.8 NaHCO3, 4.7
KCl, 1.2 MgSO4, 1.2 KH2PO4, 2.5 CaCl2, and 11.1 D-glucose) aerated with
95% O2/5% CO2 (pH 7.4) and voltage-clamped at 0 mV as described (Cox
et al., 2001; Cox and Tough, 2002). Resultant changes in ISC were measured
as mA/cm2 once preparations had stabilized (15 min). Mouse mucosae were
pretreated with secretagogue, VIP (10 nM, basolateral), and once elevated
ISC had reached its peak and was declining at a constant rate, a-MSH was
added to either the apical or basolateral reservoir to determine the sidedness
of these peptide responses. Subsequently a concentration of 1 mM a-MSH
(basolateral) was selected as the MC4R stimulus because it elicited near-
maximal responses in mouse colon. To ascertain endogenous peptides stimu-
lated by basolateral a-MSH, mucosa were pretreated with Y1 antagonist
(BIBO3304, 300 nM), Y2 antagonist (BIIE0246, 1 mM), or MC4R antagonist
(HS014, 30 nM for mouse, and 100 nM for human mucosa), each added baso-
laterally, and 20 min later PYY (10 nM) was added as a control Y1/Y2 receptor
stimulus.
To test glucose sensitivity of a-MSH (1 mM) responses, mouse colon was
bathed with KH buffer containing glucose (11.1 mM) in one reservoir and
mannitol (11.1 mM) in place of glucose in the other. PYY (10 nM) responses
weremeasured 15min after a-MSH addition and apical SGLT1 inhibitor, phlor-
idzin (50 mM, apical), was added (15 min after PYY) to confirm the requirement
of glucose for this inhibitory activity.
ISC responses in mA are expressed as the mean ± SEM per unit area
(cm2). Single comparisons (using GraphPad Prism) were performed using
Student’s unpaired t test while multiple comparisons utilized one-way
ANOVA with Dunnett’s post test, and p % 0.05 was consideredolism 20, 1018–1029, December 2, 2014 ª2014 Elsevier Inc. 1027
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MC4R in L Cells Regulates PYY and GLP-1 Releasestatistically significant. Animal experiments described above were per-
formed in accordance with the Animals (Scientific Procedures) Act 1986
and had approval from internal ethical committees for animal experimenta-
tion at Kings College, London. Clinical specimens were obtained from
consenting patients undergoing bowel resection surgery, approved by
the Research Ethics Committee of Guy’s & St Thomas’ NHS Foundation
Trust.
Plasma Hormone Measurements
Except when indicated, experimental mice (C57BL/6J; MC4R+/+, MC4R+/,
and MC4R/) were acclimated to handling and injections for up to 7 days
prior to blood collection. The mice were scruffed, then injected with 100–
200 ml of saline each day in order to minimize stress during final blood
collection. On the day of blood collection, mice were subjected to a 4 hr
daytime fast to reduce postprandial hormones to baseline levels. Mice
were then injected with the indicated dose of LY2112688, a-MSH, or vehicle
(saline), in 100–200 ml volumes, according to body weight. Blood was
collected from mice at times indicated, either by decapitation under deep
anesthesia from inhaled isofluorane or by submandibular bleeding in
conscious mice. Repeated sampling by submandibular bleeding was done
at least 2 weeks apart to allow for complete recovery from blood loss.
Blood was collected into tubes containing appropriate volumes of EDTA,
Protease Inhibitor Cocktail (Sigma, P8340), and DPP-IV Inhibitor (Millipore,
catalog number DPP4) and kept on ice. Upon completion of blood collec-
tion, the tubes containing blood, EDTA, and protease inhibitors were spun
at 3000 3 g at 4C for 30 min. Plasma was removed and spun at
10,000 3 g at 4C for 1 min to pellet remaining blood cells. Plasma was
frozen at 80C until use. Plasma hormones were assayed using the Milli-
plexMAP Mouse Metabolic Hormone–Magnetic Bead Panel Immunoassay
(Millipore MMHMAG-44K), with duplicate 10 ml samples of undiluted plasma
to detect any combination of hormones including PYY (total), GLP-1, ghre-
lin, amylin (active), GIP, insulin, and leptin. The assay was read on a Lumi-
nex 100 analyzer. Total GLP-1 levels were also assayed separately with
greater sensitivity using an ELISA kit (Millipore EZGLP1T-36K). Values
were plotted in GraphPad Prism, and statistical analyses were conducted
using ANOVA with Bonferroni posttest between all experimental groups,
or by t test when only two groups were available. The animal procedures
described above were approved by the Vanderbilt University Animal Care
and Use Committee.
Intracerebroventricular Injections
Mice (9-week-old C57BL/6J) with third ventricle i.c.v. cannulation were ob-
tained from Jackson Labs. After acclimatization to handling and manipulation
of the cannula for several days, mice were fasted (4 hr). Each mouse was then
given an i.c.v. injection (10 nmol SHU9119 or LY2112688 in saline) in a volume
of 2 mL, followed by an i.p. injection (3 mg/kg LY2112688 or saline) in a volume
of 100 mL. Submandibular bleeds were performed 10 min later. In a parallel
study, the same group of mice received an i.c.v. injection (3 nmol MTII or sa-
line), followed by an i.p. injection of saline. Submandibular bleeds were per-
formed after 10 min. Plasma was assayed for PYY levels as before. The animal
procedures described above were approved by the Vanderbilt University An-
imal Care and Use Committee.
Materials
BIBO3304 and BIIE0246 (Tocris Bioscience) were dissolved in 10% DMSO (at
1 mM) and stored at 20C. Peptide stocks of LY211688 (Bachem Labora-
tories), a-MSH (Abcam), HS014 (Tocris Bioscience), NDP-a-MSH, ACTH and
MT II (Phoenix Pharmaceuticals), VIP, and PYY (Cambridge Bioscience)
were dissolved in water, and aliquots were stored at 20C. PSN632408
(Cayman Chemical) was dissolved in 95% ethanol. All other compounds
were of analytical grade (Sigma-Aldrich).
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